Cargando…
Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2
BACKGROUND: Mutations in the genes PRKN and LRRK2 are the most frequent known genetic lesions among Parkinson's disease patients. We have previously reported that in the Portuguese population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequencies in Europe. METHODS: Here...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248204/ https://www.ncbi.nlm.nih.gov/pubmed/18211709 http://dx.doi.org/10.1186/1471-2377-8-1 |
_version_ | 1782150979704061952 |
---|---|
author | Bras, Jose Guerreiro, Rita Ribeiro, Maria Morgadinho, Ana Januario, Cristina Dias, Margarida Calado, Ana Semedo, Cristina Oliveira, Catarina Hardy, John Singleton, Andrew |
author_facet | Bras, Jose Guerreiro, Rita Ribeiro, Maria Morgadinho, Ana Januario, Cristina Dias, Margarida Calado, Ana Semedo, Cristina Oliveira, Catarina Hardy, John Singleton, Andrew |
author_sort | Bras, Jose |
collection | PubMed |
description | BACKGROUND: Mutations in the genes PRKN and LRRK2 are the most frequent known genetic lesions among Parkinson's disease patients. We have previously reported that in the Portuguese population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequencies in Europe. METHODS: Here, we follow up on those results, screening not only LRRK2, but also PRKN, SNCA and PINK1 in a cohort of early-onset and late-onset familial Portuguese Parkinson disease patients. This series comprises 66 patients selected from a consecutive series of 132 patients. This selection was made in order to include only early onset patients (age at onset below 50 years) or late-onset patients with a positive family history (at least one affected relative). All genes were sequenced bi-directionally, and, additionally, SNCA, PRKN and PINK1 were subjected to gene dosage analysis. RESULTS: We found mutations both in LRRK2 and PRKN, while the remaining genes yielded no mutations. Seven of the studied patients showed pathogenic mutations, in homozygosity or compound heterozygosity for PRKN, and heterozygosity for LRRK2. CONCLUSION: Mutations are common in Portuguese patients with Parkinson's disease, and these results clearly have implications not only for the genetic diagnosis, but also for the genetic counseling of these patients. |
format | Text |
id | pubmed-2248204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22482042008-02-20 Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 Bras, Jose Guerreiro, Rita Ribeiro, Maria Morgadinho, Ana Januario, Cristina Dias, Margarida Calado, Ana Semedo, Cristina Oliveira, Catarina Hardy, John Singleton, Andrew BMC Neurol Research Article BACKGROUND: Mutations in the genes PRKN and LRRK2 are the most frequent known genetic lesions among Parkinson's disease patients. We have previously reported that in the Portuguese population the LRRK2 c.6055G > A; p.G2019S mutation has one of the highest frequencies in Europe. METHODS: Here, we follow up on those results, screening not only LRRK2, but also PRKN, SNCA and PINK1 in a cohort of early-onset and late-onset familial Portuguese Parkinson disease patients. This series comprises 66 patients selected from a consecutive series of 132 patients. This selection was made in order to include only early onset patients (age at onset below 50 years) or late-onset patients with a positive family history (at least one affected relative). All genes were sequenced bi-directionally, and, additionally, SNCA, PRKN and PINK1 were subjected to gene dosage analysis. RESULTS: We found mutations both in LRRK2 and PRKN, while the remaining genes yielded no mutations. Seven of the studied patients showed pathogenic mutations, in homozygosity or compound heterozygosity for PRKN, and heterozygosity for LRRK2. CONCLUSION: Mutations are common in Portuguese patients with Parkinson's disease, and these results clearly have implications not only for the genetic diagnosis, but also for the genetic counseling of these patients. BioMed Central 2008-01-22 /pmc/articles/PMC2248204/ /pubmed/18211709 http://dx.doi.org/10.1186/1471-2377-8-1 Text en Copyright © 2008 Bras et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Bras, Jose Guerreiro, Rita Ribeiro, Maria Morgadinho, Ana Januario, Cristina Dias, Margarida Calado, Ana Semedo, Cristina Oliveira, Catarina Hardy, John Singleton, Andrew Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 |
title | Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 |
title_full | Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 |
title_fullStr | Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 |
title_full_unstemmed | Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 |
title_short | Analysis of Parkinson disease patients from Portugal for mutations in SNCA, PRKN, PINK1 and LRRK2 |
title_sort | analysis of parkinson disease patients from portugal for mutations in snca, prkn, pink1 and lrrk2 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2248204/ https://www.ncbi.nlm.nih.gov/pubmed/18211709 http://dx.doi.org/10.1186/1471-2377-8-1 |
work_keys_str_mv | AT brasjose analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT guerreirorita analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT ribeiromaria analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT morgadinhoana analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT januariocristina analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT diasmargarida analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT caladoana analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT semedocristina analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT oliveiracatarina analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT hardyjohn analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 AT singletonandrew analysisofparkinsondiseasepatientsfromportugalformutationsinsncaprknpink1andlrrk2 |